A Promising Drug Target: CENPA for Chromosomal Abnormalities (G1058)

Target Name: CENPA

NCBI ID: G1058

CENPA

A Promising Drug Target: CENPA for Chromosomal Abnormalities

A Promising Drug Target: CENPA, the Renlan autoantigen (Centromere Autoantigen), for the Treatment of Chromosomal Abnormalities

Introduction

Chromosomal abnormalities, such as Down syndrome, are common genetic disorders that affect millions of people worldwide. These disorders are often caused by the presence of extra or missing chromosomes, which can lead to the development of various health problems, including developmental delays, cognitive impairments , and chronic diseases. Chromosomal abnormalities can also be caused by mutations, which can lead to the formation of aberrant proteins and contribute to the development of cancer.

Recent studies have identified CENPA, a rennan autoantigen (Centromere Autoantigen), as a promising drug target for the treatment of chromosomal abnormalities. CENPA is a non-coding RNA molecule that is located at the center of chromosomes and plays a critical role in the regulation of chromosome structure and function. It has been shown to be involved in the development and progression of various chromosomal abnormalities, including Down syndrome.

The search for a drug target for chromosomal abnormalities has led to the identification of numerous potential therapeutic compounds, many of which have been tested in clinical trials. However, the challenge is to identify those compounds that are safe, effective, and have minimal side effects . This is where CENPA comes in.

CENPA: A Drug Target for Chromosomal Abnormalities

CENPA has been shown to be involved in the development and progression of various chromosomal abnormalities, including Down syndrome, Fragile X syndrome, and P95T2122 syndrome. It has also been shown to play a role in the regulation of chromosome structure and function, which is essential for the proper functioning of the chromosomes.

One of the key features of CENPA is its ability to interact with the protein cohesin, which is a component of the chromosome. This interaction allows CENPA to physically interact with the cohesin and help to maintain the integrity of the chromosome. Studies have shown that the The presence of CENPA at the center of chromosomes is critical for the proper formation and function of the chromosomes.

CENPA has also been shown to play a role in the regulation of gene expression. Studies have shown that CENPA can interact with the RNA polymerase, which is responsible for transcribing DNA into RNA. This interaction allows CENPA to regulate the expression of genes that are critical for the development and progression of chromosomal abnormalities.

CENPA as a Potential Drug Target

The identification of CENPA as a potential drug target for chromosomal abnormalities has led to a great deal of interest in the development of compounds that can interact with CENPA and prevent or reverse the development of chromosomal abnormalities.

One of the challenges in the development of a drug target for CENPA is the understanding of its complex interactions with the chromosome and the cell. To overcome this challenge, researchers have used a variety of techniques, including in vitro studies and live-cell imaging, to gain a better understanding of the behavior of CENPA in the chromosome and the cell.

In vitro studies have shown that CENPA can interact with the protein cohesin and the RNA polymerase, which is responsible for transcribing DNA into RNA. These interactions are critical for the proper functioning of the chromosome. Studies have also shown that the presence of CENPA at the center of chromosomes is essential for the proper formation and function of the chromosome.

Live-cell imaging has also been used to study the behavior of CENPA in the chromosome and the cell. Studies have shown that CENPA can physically interact with the cohesin and the RNA polymerase,

Protein Name: Centromere Protein A

Functions: Histone H3-like nucleosomal protein that is specifically found in centromeric nucleosomes (PubMed:7962047, PubMed:9024683, PubMed:11756469, PubMed:14667408, PubMed:15702419, PubMed:15475964, PubMed:15282608, PubMed:17651496, PubMed:19114591, PubMed:27499292, PubMed:20739937). Replaces conventional H3 in the nucleosome core of centromeric chromatin that serves as an assembly site for the inner kinetochore (PubMed:18072184). The presence of CENPA subtly modifies the nucleosome structure and the way DNA is wrapped around the nucleosome and gives rise to protruding DNA ends that are less well-ordered and rigid compared to nucleosomes containing histone H3 (PubMed:27499292, PubMed:26878239). May serve as an epigenetic mark that propagates centromere identity through replication and cell division (PubMed:15475964, PubMed:15282608, PubMed:26878239, PubMed:20739937, PubMed:21478274). Required for recruitment and assembly of kinetochore proteins, and as a consequence required for progress through mitosis, chromosome segregation and cytokinesis (PubMed:11756469, PubMed:14667408, PubMed:18072184, PubMed:23818633, PubMed:25556658, PubMed:27499292)

The "CENPA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CENPA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets